fasudil has been researched along with Invasiveness, Neoplasm in 11 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil plays an important role in interfering BTBD7-ROCK2 signaling pathway and suppressing the invasion and metastasis of hepatocellular carcinoma." | 7.80 | [Suppression of hepatocellular carcinoma invasion and metastasis by Rho-kinase inhibitor Fasudil through inhibition of BTBD7-ROCK2 signaling pathway]. ( Hu, K; Tao, Y; Wang, Z, 2014) |
| "Fasudil plays an important role in interfering BTBD7-ROCK2 signaling pathway and suppressing the invasion and metastasis of hepatocellular carcinoma." | 3.80 | [Suppression of hepatocellular carcinoma invasion and metastasis by Rho-kinase inhibitor Fasudil through inhibition of BTBD7-ROCK2 signaling pathway]. ( Hu, K; Tao, Y; Wang, Z, 2014) |
| "Injected human leukemic and breast cancer cells exhibited cell-type specific patterns of intravascular distribution with leukemic cells moving faster than breast cancer cells." | 1.56 | Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenografts. ( Asokan, N; Bernas, SN; Bornhäuser, M; Brand, M; Daetwyler, S; Huisken, J; Kempermann, G; Lambert, K; Schmied, C; Vogler, S; Wermke, M; Wobus, M, 2020) |
| "Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response." | 1.46 | Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. ( Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A, 2017) |
| "Oral squamous cell carcinoma (OSCC) is the most malignant lesion occurring in the head and neck." | 1.42 | HA-1077 inhibits cell migration/invasion of oral squamous cell carcinoma. ( Crema, VO; Moreira Carboni, Sde S; Pinheiro, NM; Rodrigues Lima, NA; Tavares-Murta, BM, 2015) |
| "After treatment to NCI-H446 small cell lung cancer cells with Fasudil, a Rho-kinase inhibitor, cell biological behaviors were observed." | 1.38 | The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. ( Di, J; Liu, J; Lu, J; Shi, W; Yang, X; Zhang, S; Zhang, Y, 2012) |
| "Fasudil is a kind of Rho kinase inhibitor." | 1.37 | Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. ( Li, Z; Nong, L; Ren, J; Wu, G; Zhang, R; Zhang, Z; Zhu, F, 2011) |
| "The poor prognosis of advanced ovarian cancer comes from increased invasiveness of human ovarian cancer cells." | 1.35 | Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. ( Hashimoto, K; Kawase, C; Kimura, T; Mabuchi, S; Morishige, K; Ogata, S; Ooyagi, C; Sakata, M; Sawada, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, N | 1 |
| Takeda, K | 1 |
| Imai, M | 1 |
| Asokan, N | 1 |
| Daetwyler, S | 1 |
| Bernas, SN | 1 |
| Schmied, C | 1 |
| Vogler, S | 1 |
| Lambert, K | 1 |
| Wobus, M | 1 |
| Wermke, M | 1 |
| Kempermann, G | 1 |
| Huisken, J | 1 |
| Brand, M | 1 |
| Bornhäuser, M | 1 |
| Poisson, L | 1 |
| Lopez-Charcas, O | 1 |
| Chadet, S | 1 |
| Bon, E | 1 |
| Lemoine, R | 1 |
| Brisson, L | 1 |
| Ouaissi, M | 1 |
| Baron, C | 1 |
| Besson, P | 1 |
| Roger, S | 1 |
| Moussata, D | 1 |
| Vennin, C | 1 |
| Chin, VT | 1 |
| Warren, SC | 1 |
| Lucas, MC | 1 |
| Herrmann, D | 1 |
| Magenau, A | 1 |
| Melenec, P | 1 |
| Walters, SN | 1 |
| Del Monte-Nieto, G | 1 |
| Conway, JR | 1 |
| Nobis, M | 1 |
| Allam, AH | 1 |
| McCloy, RA | 1 |
| Currey, N | 1 |
| Pinese, M | 1 |
| Boulghourjian, A | 1 |
| Zaratzian, A | 1 |
| Adam, AA | 1 |
| Heu, C | 1 |
| Nagrial, AM | 1 |
| Chou, A | 1 |
| Steinmann, A | 1 |
| Drury, A | 1 |
| Froio, D | 1 |
| Giry-Laterriere, M | 1 |
| Harris, NL | 1 |
| Phan, T | 1 |
| Jain, R | 1 |
| Weninger, W | 1 |
| McGhee, EJ | 1 |
| Whan, R | 1 |
| Johns, AL | 1 |
| Samra, JS | 1 |
| Chantrill, L | 1 |
| Gill, AJ | 1 |
| Kohonen-Corish, M | 1 |
| Harvey, RP | 1 |
| Biankin, AV | 1 |
| Evans, TR | 1 |
| Anderson, KI | 1 |
| Grey, ST | 1 |
| Ormandy, CJ | 1 |
| Gallego-Ortega, D | 1 |
| Wang, Y | 1 |
| Samuel, MS | 1 |
| Sansom, OJ | 1 |
| Burgess, A | 1 |
| Cox, TR | 1 |
| Morton, JP | 1 |
| Pajic, M | 1 |
| Timpson, P | 1 |
| Hu, K | 1 |
| Wang, Z | 1 |
| Tao, Y | 1 |
| Moreira Carboni, Sde S | 1 |
| Rodrigues Lima, NA | 1 |
| Pinheiro, NM | 1 |
| Tavares-Murta, BM | 1 |
| Crema, VO | 1 |
| Ogata, S | 1 |
| Morishige, K | 1 |
| Sawada, K | 1 |
| Hashimoto, K | 1 |
| Mabuchi, S | 1 |
| Kawase, C | 1 |
| Ooyagi, C | 1 |
| Sakata, M | 1 |
| Kimura, T | 1 |
| Zhu, F | 1 |
| Zhang, Z | 1 |
| Wu, G | 1 |
| Li, Z | 1 |
| Zhang, R | 1 |
| Ren, J | 1 |
| Nong, L | 1 |
| Yang, X | 2 |
| Zhang, Y | 2 |
| Wang, S | 1 |
| Shi, W | 2 |
| Heikkila, T | 1 |
| Wheatley, E | 1 |
| Crighton, D | 1 |
| Schroder, E | 1 |
| Boakes, A | 1 |
| Kaye, SJ | 1 |
| Mezna, M | 1 |
| Pang, L | 1 |
| Rushbrooke, M | 1 |
| Turnbull, A | 1 |
| Olson, MF | 1 |
| Di, J | 1 |
| Zhang, S | 1 |
| Lu, J | 1 |
| Liu, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for fasudil and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
Topics: Aminophenols; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibrosarcoma; | 2013 |
Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenografts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Tra | 2020 |
Rock inhibition promotes Na
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Cell Line, Tumor; Cell Movement; Colonic Neop | 2020 |
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals | 2017 |
[Suppression of hepatocellular carcinoma invasion and metastasis by Rho-kinase inhibitor Fasudil through inhibition of BTBD7-ROCK2 signaling pathway].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adaptor Proteins, Signal Transducing; Carcinoma, Hepa | 2014 |
HA-1077 inhibits cell migration/invasion of oral squamous cell carcinoma.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Antineoplastic Agents; Carcinoma, | 2015 |
Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Carcinoma; Cell Movem | 2009 |
Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Blotting, Western; Cell Line, | 2011 |
Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Carcinoma; Cell Adhesion; Cell | 2010 |
Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Catalytic Domain; Cell Line, Tumor; Collagen; | 2011 |
The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Caspase 3; Cell Adhesion; Cell Line, Tumor | 2012 |